Our ENHANZE enzyme rHuPH20 is listed by the FDA as an active ingredient in various combination products. Closing out these highlights. I'm also delighted to announce that our clinical tests of a high volume auto-injector was a success, confirming both the feasibility and tolerability of rapid injection of 10 milliliters of a biologic with our high volume auto-injector. All of this progress strengthens our confidence in achieving our updated full year 2023 financial guidance, where we have raised our non-GAAP EPS range and increase the lower end of the range for total revenue and for EBITDA. With that summary, let me provide some details on the events during the quarter that are driving revenue in 2023 and beyond. Turning to Slide four. Halozyme is a leading drug delivery platform company with a diversified and robust portfolio, which includes our ENHANZE royalty business, our auto-injector technology business and our specialty commercial products.